In search of new strategies against life-threatening tuberculosis infections, a team from the Technical University of Munich (TUM), as well as Harvard University and Texas A&M University in the USA have found a new ally. They discovered a substance that interferes with the mycomembrane formation of the bacterium. It is effective even in low concentrations and when combined with known antibiotics their effectiveness is improved by up to 100-fold.
Among the greatest challenges when treating life-threatening tuberculosis infections is the increasing resistance to antibiotics. But the pathogen itself also makes the life of doctors difficult: its dense mycomembrane hampers the effect of many medications. A team of scientists headed by Stephan A. Sieber, Professor of Organic Chemistry at TU Munich, has discovered a substance that perturbs the formation of this membrane significantly.
The mycomembrane of the tuberculosis pathogen Mycobacterium tuberculosis consists of a lipid double layer that encapsulates the cell wall, forming an exterior barrier. Structural hallmarks are mycolic acids, branched beta-hydroxy fatty acids with two long hydrocarbon chains. The team hypothesizes that similarly structured beta lactones could “mask” themselves as mycolic acid to enter the mycolic acid metabolic pathways and then block the decisive enzymes.
HELPFUL DISRUPTER
In the context of an extensive search, the interdisciplinary team of scientists hit the bullseye with the beta lactone EZ120. It does indeed inhibit the biosynthesis of the mycomembrane and kills mycobacteria effectively. Using enzyme assays and mass spectroscopy investigations, Dr. Johannes Lehmann, a researcher at the Chair of Organic Chemistry II at TU Munich, demonstrated during his doctoral work that the new inhibitor blocks especially the enzymes Pks13 and Ag85, which play a key role in the development of mycomembranes.
EZ120 is effective even in low doses, easily passes the mycomembrane and exhibits only low toxicity to human cells. The combined application of this substance with known antibiotics showed a synergistic effect leading to significantly increased effectiveness.”Vancomycin, a common antibiotic, and EZ120 work together very well,” says Prof. Sieber, who heads the Chair of Organic Chemistry II. “When used together, the dose can be reduced over 100-fold.
“The scientists suspect that disrupting the mycomembrane enables antibiotics to enter the bacteria more easily. This is a new mode of action and might be a starting point for novel tuberculosis therapies.
Learn more: Double strike against tuberculosis
The Latest on: Tuberculosis
[google_news title=”” keyword=”tuberculosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Tuberculosis case reported at high school in North Carolinaon May 8, 2024 at 9:31 pm
A positive case of tuberculosis (TB) has been identified at a school in Randolph County. Leaders with the Randolph County Public Health system said the case was identified at Eastern Randolph High School, adding person with TB has not been in attendance ...
- Overcoming barriers to scaling up tuberculosis preventive treatment for household contactson May 8, 2024 at 4:22 pm
Approximately a quarter of the world's population is infected with tuberculosis, which is the seedbed from which all forms of tuberculosis disease develops.1,2 Treatment of tuberculosis infection, known as preventive treatment,
- At least 14 sickened from outbreak of tuberculosison May 8, 2024 at 3:06 pm
As of April 29, 14 cases were found in Long Beach, according to The Los Angeles Times. Another 170 people were possibly exposed to tuberculosis. Of the 14 cases, nine have been hospitalized and one person has died, NBC News reported.
- ICMR study leads to unique non-invasive method of SmaRT-PCR mask to detect tuberculosis in childrenon May 8, 2024 at 8:23 am
The mask is a modified version of N95 mask with a special gelatin membrane inside which collects all exhaled respiratory aerosols. This method of diagnosis, which was rolled out on a pilot basis, is c
- Shortage Of TB Medicines: Patients Rely On Double Dose Of Paediatric Medicines To Fight Tuberculosison May 7, 2024 at 2:15 pm
Acute shortage of regular medicines has forced more than 2,700 patients in Indore to turn to paediatric medicines’ double dose to fight tuberculosis.The scarcity is already two months old with no solution in sight.
- GSK expands collaboration with BioVersys on tuberculosis asset alpibectiron May 7, 2024 at 11:08 am
GSK (NYSE:GSK) will expand its collaboration with BioVersys AG on the development of tuberculosis candidate alpibectir as well as take an equity stake in the Swiss biopharma's latest round. BioVersys said the GSK investment of CHF 12.
- Hidden Figures Of Healthcare: Meet The Black Nurses Who Helped Cure Tuberculosison May 7, 2024 at 8:15 am
Until recently, the stories of these Black nurses went largely untold. The book "Black Angels" shares how they helped save countless lives despite discrimination.
via Google News and Bing News